ArticleDrug and alcohol dependence2025
Prevalence of congenital heart defects among children with and without diagnosed fetal alcohol spectrum disorders, 2016-2022.
Article in Drug and alcohol dependence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cardiovascular and Cardiometabolic Outcomes in Adults with Fetal Alcohol Spectrum Disorders: A Retrospective Cohort Study.medRxiv : the preprint server for health sciences · 2026Article
- Comprehensive Analysis of the Placenta-Cortex Transcriptomic Database Reveals a Neuroactive Ligand-Receptor Dysregulation After Prenatal Alcohol Exposure.International journal of molecular sciences · 2026Article
- Betaine as a regulator of metabolism, epigenetics, and cellular osmoprotection: therapeutic implications in cardiometabolic and renal diseases.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAlcohol use during pregnancy might be a risk factor for some congenital heart defects (CHDs), but CHD prevalence among children with fetal alcohol spectrum disorders (FASDs) is not well understood. We used two administrative databases to explore CHD prevalence among U.S. children with and without FASDs.
methodsWe limited 2016-2022 Merative™ MarketScan® Multi-State Medicaid and Commercial data to children ≤ 17 years old with ≥ 1 year of continuous enrollment with complete data on mental health and substance use services. CHD prevalence was calculated by FASD status, overall and by age group, using log-binomial prevalence ratios (PRs) and 95 % confidence intervals (CIs). Analyses were repeated after matching on enrollment length, and age and year at the start of enrollment. In the Medicaid sample, we also stratified by demographic characteristics and analyzed severe and non-severe CHD diagnoses separately. Multidimensional bias analysis considered the influence of unmeasured prenatal tobacco exposure.
resultsAmong 8732,345 children in the Medicaid sample, 5.2 % with FASDs and 1.0 % without FASDs had CHDs (matched cohort PR = 3.4 [CI: 2.8, 4.1]). PRs were similar when stratified by sex and race and ethnicity, and when looking at exclusively severe or non-severe CHDs. Among 10,567,765 children in the commercial claims sample, 3.0 % with FASDs and 0.6 % without FASDs had CHDs (matched cohort PR= 4.6 [CI: 3.3, 6.4]).
conclusionCHDs were more common among children with FASDs compared to those without FASDs in two administrative database samples. Increased provider awareness about CHDs as a potential FASD comorbidity may improve timely CHD care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.